Premature Babies Used As Lab Rats By GlaxoSmithKline

How do these pharmacy corporations expect to get away with it?

While reading the results of a vaccination trial on premature babies funded by GlaxoSmithKline, I noticed something was not quite right.

The trial, whilst sickening in itself, was testing out the rotavirus vaccine on a group of 988 premature babies ranging between 27 weeks and 36 weeks.

The paper reporting the trial was published on the ‘Pediatric SuperSite’ and was entitled ‘Human rotavirus immunogenic, well-tolerated for preterm infants’ by Felix Omenaca MD. PhD, and colleagues (1) The paper stated the following:

“The researchers grouped preterm infants by ages — infants born at gestational ages 27 to 30 weeks and those born at 30 to 36 weeks. They administered rotavirus vaccine (RIX4414, GlaxoSmithKline) in two doses to 658 preterm infants, and 330 received a placebo along with routine vaccinations, including diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type B and poliovirus. Infants from France and Spain also received Streptococcus pneumoniae concomitantly; infants from Portugal and Spain also received Neisseria meningitides.

The researchers then asked parents/guardians to report adverse effects, and they noted no statistically significant difference in the reporting of severe adverse reactions in the vaccine or placebo group (5.1% and 6.2%, respectively). Unsolicited adverse effects, which included fever of more than 39.5·C, six or more bouts of diarrhea per day, three or more episodes of vomiting per day, appetite loss and irritability, were reported in 29.3% of preterm infants in the vaccine group and 40.7% in the placebo group. (own emphasis)

The problems I see are as follows:

All the infants were given multiple vaccinations, therefore, there was no control group.
Of a group of 988 children, approx 2/3 were given the vaccine for rotavirus and 1/3 were given the placebo, then the researchers compared the results like for like. This cannot be done because one group is significantly larger than the other.
Because all of the infants received multiple vaccinations it is impossible to tell which vaccine if any caused the side effects.
I decided to examine the exact figures in greater detail.

The total of infants given all the vaccines including the rotavirus vaccine was 658 which equal 66.6% of the total number of babies being tested.

The total of infants given all the vaccines except the rotavirus vaccine was 330 which equal 33.3% of the total number of babies being tested.

Severe Reactions

In the group receiving the rotavirus vaccine 5.1% of the infants had a severe reaction; this was a total of 33 children.

In the group receiving the placebo 6.2% of the infants had a severe reaction; this was a total of 20 children.

Less Severe Reactions

Now let us look at what the researchers call ‘unsolicited adverse effects’.

The researchers say that these effects included fever of more than 39.5·C, six or more bouts of diarrhea per day, three or more episodes of vomiting per day, appetite loss and irritability.

(TAP – My baby son was vaccinated at The Asian Hopsital & Medical Center without permission at birth with GSK’s Engerix-B. He suffered two days of drowsiness and loss of appetite. As these were his first two days of life, it was extremely stressful for us the parents.)

In the group receiving the rotavirus vaccine 29.3% of the infants had an unsolicited adverse effect which is a total of 192 children.

In the group receiving the placebo 40.7% of the infants had an unsolicited adverse effect which is a total of 134 children

Presuming that the children in the severe group were different to the children in the unsolicited group, this means that a total of 225 children of the 688 who received all of the vaccines including the rotavirus vaccine had an adverse reaction.

(Figures checked on Google)

This amounts to a massive number of premature babies suffering from adverse reactions and yet despite this the researchers, reported that ‘because of the higher risk that human rotavirus poses to preterm infants, the study supports this vaccine’s use in those older than 27 weeks who are “medically stable at the time of or after discharge from the neonatal unit’.
Read more at The Tap Blog

Translate »